科研动态

首页 > 科学研究 > 科研动态 > 正文

马芳博士在SCI期刊European Journal of Medicinal Chemistry发表论文

时间:2018-01-31 16:41:47 来源:英国威廉希尔公司 作者: 阅读:

 

标题:Novel deoxyvasicinone derivatives as potent multitarget-directed ligands for the treatment of Alzheimer's disease: Design, synthesis, and biological evaluation.
作者:Fang Ma, Hongtao Du
来源出版物:European Journal of Medicinal Chemistry, 140卷;页: 118-127.
DOI: org/10.1016/j.ejmech.2017.09.008
出版年: 2017
文献类型:Article
语种:English
摘要:A series of multitarget ligands was designed by introducing several structurally diverse aminoacetamide groups at position 6 of the deoxyvasicinone group, with the aim of obtaining novel multifunctional anti-Alzheimer's disease agents using deoxyvasicinone as the substrate. In vitro studies showed that almost all of the derivatives were potent inhibitors of human recombinant acetylcholinesterase (hAChE) and human serum butyrylcholinesterase (hBChE), with IC50 values in the low nanomolar range, and exhibited moderate to high inhibition of Aβ1−42 self-aggregation. In particular, compounds 12h, 12n, and 12q showed promising inhibitory activity for hAChE, with IC50 values of 5.31 ± 2.8, 4.09 ± 0.23, and 7.61 ± 0.53 nM, respectively. Compounds 12h and 12q also exhibited the greatest ability to inhibit hBChE, with IC50 values of 4.35 ± 0.32 and 2.35 ± 0.14 nM, respectively. Moreover, enzyme kinetics confirmed that compound 12q caused a mixed type of AChE inhibition, by binding to both the active sites (PAS and CAS) of AChE. Remarkably, compound 12q also demonstrated the highest potential inhibitory activity for Aβ1−42 self-aggregation (63.9 ± 4.9%, 10 μM), and it was also an excellent metal chelator.
关键词 : Alzheimer's disease; Deoxyvasicinone derivatives; Cholinesterase inhibitorsInhibition of Aβ1−42 self-aggregation; Metal chelator.
ISSN:0223-5234
影响因子:4.519(2017)
 
编辑: